ABT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

11.80B

+7.53%

1.495

+11.56%

11.20B

+8.09%

1.203

+10.37%

11.96B

+7.35%

1.382

+9.67%

Estimates Revision

The market is revising No Change the revenue expectations for Abbott Laboratories (ABT) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by -5.35%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.54%

In Past 3 Month

Stock Price

Go Down

-5.35%

In Past 3 Month

19 Analyst Rating

Wall Street analysts forecast ABT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABT is 147.24 USD with a low forecast of 136.00 USD and a high forecast of 162.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

136.00

Averages

147.24

High

162.00

Current: 0.000

Low

136.00

Averages

147.24

High

162.00

Bernstein

Lee Hambright

Outperform

maintain

$150 -> $154

2026-01-09

New

Reason

Bernstein

Lee Hambright

Price Target

$150 -> $154

2026-01-09

New

maintain

Outperform

Reason

Bernstein analyst Lee Hambright raised the firm's price target on Abbott to $154 from $150 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.

Evercore ISI

Outperform

maintain

$142 -> $144

2026-01-05

New

Reason

Evercore ISI

Price Target

$142 -> $144

2026-01-05

New

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on Abbott to $144 from $142 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

Barclays

NULL -> Overweight

upgrade

$162 -> $169

2026-01-05

New

Reason

Barclays

Price Target

$162 -> $169

2026-01-05

New

upgrade

NULL -> Overweight

Reason

Barclays raised the firm's price target on Abbott to $169 from $162 and keeps an Overweight rating on the shares. The firm upped sales and earnings estimates for Abbott in 2027 and beyond.

Needham

Buy

Hold

downgrade

2025-12-15

Reason

Needham

Price Target

2025-12-15

downgrade

Buy

Hold

Reason

Needham downgraded Haemonetics (HAE) to Hold from Buy without a price target. The firm's checks indicate rising concern around competition for Haemonetics' vascular closure devices, as Abbott (ABT) and Cordis introduce newer venous closure products supported by dedicated electrophysiology sales teams, the analyst tells investors in a research note. Although stronger Plasma and Blood Management Technologies growth may offset weakness in FY26, sustained declines in Interventional Technologies are expected to constrain FY27 revenue and EPS growth and put consensus estimates at risk, the firm says.

Jefferies

Buy

Hold

downgrade

$90 -> $105

2025-11-24

Reason

Jefferies

Price Target

$90 -> $105

2025-11-24

downgrade

Buy

Hold

Reason

Jefferies downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $90, citing the pending acquisition by Abbott (ABT). The firm thinks the takeover premium represents a win for Exact Sciences and does not expect another bidder to come over the top given precedent deal multiples.

Barclays

Overweight

maintain

$159 -> $162

2025-10-17

Reason

Barclays

Price Target

$159 -> $162

2025-10-17

maintain

Overweight

Reason

Barclays raised the firm's price target on Abbott to $162 from $159 and keeps an Overweight rating on the shares. The firm recommends using the pullback following the in-line Q3 report as a buying opportunity. The shares were discounting a slightly stronger beat for Q3, the analyst tells investors in a research note. Barclays views the business weakness as temporary, and expects Abbott's portfolio to return to growth toward the high end of its historical ranges in 2026 and beyond.

Valuation Metrics

The current forward P/E ratio for Abbott Laboratories (ABT.N) is 22.44, compared to its 5-year average forward P/E of 24.63. For a more detailed relative valuation and DCF analysis to assess Abbott Laboratories 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

24.63

Current PE

22.44

Overvalued PE

26.85

Undervalued PE

22.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

18.89

Current EV/EBITDA

17.26

Overvalued EV/EBITDA

20.23

Undervalued EV/EBITDA

17.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.83

Current PS

4.57

Overvalued PS

5.26

Undervalued PS

4.41

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ABT News & Events

Events Timeline

No data

News

3.5

01-06Globenewswire

Best ABT Launches New High-Energy Cyclotron, Advancing Nuclear Medicine

7.5

01-06Benzinga

Health Care ETFs Surge as Demand for Weight-Loss Drugs Increases

9.5

01-05Newsfilter

Abbott to Announce Q4 2025 Financial Results on January 22

People Also Watch

Frequently Asked Questions

What is Abbott Laboratories (ABT) stock price today?

The current price of ABT is 126.18 USD — it has decreased -0.68 % in the last trading day.

What is Abbott Laboratories (ABT)'s business?

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.

What is the price predicton of ABT Stock?

What is Abbott Laboratories (ABT)'s revenue for the last quarter?

Abbott Laboratories revenue for the last quarter amounts to 11.37B USD, increased 6.90 % YoY.

What is Abbott Laboratories (ABT)'s earnings per share (EPS) for the last quarter?

Abbott Laboratories. EPS for the last quarter amounts to 0.94 USD, decreased 0.00 % YoY.

What changes have occurred in the market's expectations for Abbott Laboratories (ABT)'s fundamentals?

How many employees does Abbott Laboratories (ABT). have?

Abbott Laboratories (ABT) has 114000 emplpoyees as of January 09 2026.

What is Abbott Laboratories (ABT) market cap?

Today ABT has the market capitalization of 219.41B USD.